When a Chinese Biotech Portfolio Company Cannot Raise Its Next Round

A private equity fund has invested in a Wuhan biotech company for six years. The company has valuable patents, an experienced research team and promising clinical data, but its next financing round has failed. Cash will last twelve months. The shareholder agreement contains a founder repurchase obligation and liquidation preference, but the founders do not have enough personal assets to repurchase the investment. A strategic buyer may be interested in the lead asset, while the company also owes employees, laboratories, CROs and lenders.

The fund must decide whether to provide bridge capital, force an exit, restructure the company, sell intellectual property or prepare for insolvency. This is not a generic PE exit issue. It is a downside decision involving fund governance, company law, creditor priority and enterprise value. ^[2]

Start with a thirteen-week cash flow. Before analyzing legal remedies, the investor needs a realistic liquidity forecast. Monthly management accounts can hide an imminent cash problem if trial payments, payroll or milestone obligations fall unevenly. A thirteen-week cash flow should identify cash on hand, committed expenses, mandatory payroll, tax, debt service, laboratory costs and likely customer or grant receipts.

The specific issue#

Cash runway, capital structure and repurchase economics#

The legal team should use this cash view to determine when the company may become unable to pay due debts and whether new funding must be treated as rescue capital rather than ordinary growth financing.

Map the capital structure and creditor hierarchy. Prepare a schedule of equity classes, shareholder loans, bank debt, secured claims, trade creditors, employee obligations and government funding conditions. Investor preference rights in a shareholder agreement do not automatically determine priority in insolvency. Contractual liquidation preferences operate within the corporate and insolvency framework and cannot simply reorder statutory creditor rights.

The fund should distinguish its position as shareholder from any separate position as lender or secured creditor.

Test whether the repurchase right has real value. A founder repurchase clause may look attractive until the company is distressed. The fund should identify the obligor, trigger, price formula, security and actual asset position. If the founder cannot pay, aggressive enforcement may consume time while the company's enterprise value deteriorates.

A repurchase claim can still provide leverage, but the investment committee should value it based on collectability rather than face amount.

Review fund-level authority before providing bridge capital. The Private Investment Fund Regulation requires managers to act with due care and in investors' interests. The fund agreement may also limit follow-on investment after the investment period or require LP advisory committee approval for conflicts. ^[1]

Before funding again, the manager should document the legal authority, commercial rationale, valuation and expected use of proceeds. Bridge financing should not be advanced simply because the existing investment team wants more time.

Decide whether new money should be equity or debt. New equity can dilute existing shareholders and may require valuation agreement. Shareholder debt can create repayment rights but may still rank behind secured creditors and be vulnerable if the company later enters insolvency. Convertible instruments may preserve flexibility but add complexity.

The choice should follow the rescue plan. If the company needs six months to complete a strategic sale, short-term secured or contractually protected financing may be different from funding another multi-year clinical program.

Bridge capital, milestones and value leakage#

Condition bridge capital on milestones. A rescue financing should have defined milestones: completion of a licensing transaction, submission of regulatory materials, reduction of burn rate, appointment of an adviser or signing of a strategic term sheet. Tranches can be released only when milestones are met.

This prevents the fund from committing all remaining capital before evidence shows that the rescue path is working.

Protect against value leakage. Distressed companies can lose value through related-party payments, founder transactions, unusual bonuses or transfer of IP. The fund should review board approval, bank controls and related-party arrangements before providing additional money.

Reserved matters should be used to protect enterprise value, not to micromanage ordinary spending. Emergency cash controls may nevertheless be justified when runway is short.

Intellectual property may be the main realizable asset. For biotech, patents, data and regulatory dossiers can be more valuable than the operating company. The fund should identify ownership, licenses, security interests, co-development rights and change-of-control restrictions.

If a strategic buyer wants only one asset, an IP or business transfer may generate better recovery than selling the whole company. The company must still retain enough value or consideration to satisfy creditor obligations lawfully.

Key employees can determine asset value. A patent portfolio without the scientists who understand it may be less valuable. The rescue plan should identify critical researchers, regulatory personnel and management. Retention bonuses or short-term incentives may be commercially justified, but they should be approved transparently and budgeted against creditor interests.

The fund should also examine whether key employees hold inventions, data or know-how that the company has not properly documented.

Strategic sale versus insolvency#

Strategic sale and insolvency should be run in parallel initially. Management often wants to choose one path too early. A controlled dual-track process can test strategic buyer interest while preparing insolvency options if the sale fails. The company can organize a data room, appoint advisers and clean IP ownership while also identifying creditors and claim risks.

This preserves optionality and reduces the risk that the company runs out of cash before a legal process is ready.

Consider whether the business is actually reorganizable. A judicial reorganization makes sense only if going-concern value exceeds liquidation value and the company has a credible operating or transaction plan. A biotech company with one failed asset and no pipeline may not be reorganizable merely because investors prefer to avoid liquidation. ^[3]

The fund should commission an honest valuation of IP, licenses, personnel and future financing needs.

Enterprise Bankruptcy Law changes the negotiating framework. China's Enterprise Bankruptcy Law governs acceptance, claim filing, secured rights, creditor meetings, reorganization and liquidation. Once a case is accepted, individual enforcement is affected by the collective process. The fund should therefore analyze remedies before filing or encouraging a creditor to file.

A shareholder who waits until proceedings begin may lose leverage over transaction timing and rescue financing.

Secured creditors need an early seat at the table. If a bank has security over equipment, receivables or IP, the strategic sale cannot ignore that position. The company should determine payoff, release and consent requirements. A buyer may require assets free of encumbrance.

Engaging the secured creditor early can also reveal whether the lender would support standstill, new financing or a restructuring plan.

Operational creditors, grants and board duties#

Trade creditors may be operationally critical. CROs, laboratories, suppliers and clinical partners may hold ordinary unsecured claims but control data, samples or ongoing services essential to preserving enterprise value. The company should identify which creditors must continue performing during a rescue.

Selective payment must be analyzed carefully in light of insolvency risk and applicable avoidance rules. Legal and financial advisers should design any critical-vendor strategy with that risk in mind.

Government grants and subsidies can impose conditions. Biotech companies may receive research grants, talent subsidies or industrial park support. The legal team should review whether asset sale, relocation, change of control or liquidation creates repayment or approval obligations.

These commitments can reduce net sale proceeds and should be included in the recovery model.

Board duties become more important as distress deepens. Directors and management should document decisions, conflicts and the basis for continuing operations. A plan that assumes a financing will close without evidence can worsen creditor losses. Conversely, stopping a viable program too early can destroy value.

The board should receive regular cash, financing and transaction reports and record why each major decision is considered in the company's interests.

Worked failed-Series-D scenario#

Case study: failed Series D. Assume the company needs RMB 80 million to reach a regulatory milestone but has only RMB 25 million cash. The fund can invest RMB 20 million more. A pharmaceutical company offers RMB 120 million for one patent family and related data, while the founders insist the company is worth RMB 600 million if it can survive another year.

The fund should compare three scenarios: bridge financing toward the milestone, immediate asset sale, and formal restructuring. The comparison should include probability-adjusted value, required new money, creditor payments and time—not founder expectations alone.

Repurchase litigation, LP reporting and fund-term conflicts#

Repurchase litigation may undermine a strategic sale. If the fund sues the founders immediately and freezes shares or assets, a strategic buyer may perceive the company as uninvestable. Enforcement may still be necessary, but timing should be coordinated with the value-maximizing exit path.

The fund should decide whether repurchase rights are the primary recovery route or negotiating leverage supporting a broader transaction.

LP reporting must be candid. The fund manager should explain the deterioration, valuation basis, bridge-financing decision and expected exit scenarios to LPs in accordance with the fund documents and regulatory obligations. Avoid presenting an extension as routine if the investment is materially impaired.

State-owned LPs may require additional internal reporting or valuation support.

Fund-term pressure can create conflicts. If the fund is near the end of its term, the manager may prefer a quick exit even if a longer restructuring could create more value. Conversely, continued management fees can create an incentive to delay. The governance process should address these conflicts transparently.

An LP advisory committee or investor vote may be appropriate where the fund agreement requires it.

Secondary transfer can be an alternative. The fund may sell its portfolio interest or fund interest to a secondary buyer that has a longer time horizon. The buyer will discount for distress and legal complexity but can provide liquidity without forcing the company into a premature asset sale.

Consent, transfer restrictions and valuation should be reviewed before launching a secondary process.

Insolvency data room, recovery waterfall and stop point#

Prepare the insolvency data room before filing. The company should organize corporate records, creditor lists, security, employee claims, tax, IP, licenses, litigation and financial statements. A chaotic filing can destroy confidence and delay reorganization.

The same data room supports strategic buyers, so preparation is useful even if formal insolvency is avoided.

Create a recovery waterfall by scenario. For each scenario—standalone financing, asset sale, share sale, reorganization and liquidation—calculate estimated proceeds, costs, secured creditor recovery, employee and tax claims, ordinary creditor recovery and shareholder residual.

The fund's investment committee should make decisions from this waterfall, not headline company valuation.

Define the point at which rescue should stop. Bridge financing should have a stop-loss rule. If no buyer, licensing deal or next financing is achieved by a defined date, the board and fund should reassess rather than committing successive emergency tranches.

The rule protects LP capital and reduces the risk that new money merely pays old liabilities without preserving enterprise value.

Company value, preferred rights and founder conduct#

Separate company value from fund accounting value. The fund's last reported NAV may reflect a financing round that is no longer relevant. Before authorizing new money, the manager should obtain a current enterprise-value range using realistic transaction assumptions. A distressed biotech company with a high historic preferred share price may have little value if its lead asset has failed or licensing markets have changed.

The investment committee should document any write-down rather than using bridge capital to postpone recognition of deterioration. Accurate valuation also affects LP reporting and any secondary transfer.

Preferred shareholder rights should be mapped against Company Law. Investment agreements may provide veto rights, liquidation preferences, anti-dilution and information rights. The fund should identify which rights operate contractually between shareholders, which are reflected in the articles and which may be constrained in insolvency.

A preference that works in a solvent exit may not produce the same economic result after formal bankruptcy. Counsel should distinguish contractual leverage from statutory priority.

Founder conduct can determine whether continued funding is rational. Bridge capital should normally require enhanced reporting and restrictions on extraordinary transactions. If founders resist transparency, move assets to affiliates or continue spending outside the rescue plan, the fund should reconsider whether further capital can be protected.

The rescue decision depends not only on technology but on management credibility and governance.

Regulatory milestones, asset sales and licensing alternatives#

Regulatory milestones should be independently verified. Biotech management may project approval dates optimistically. The fund should verify clinical, regulatory and manufacturing milestones with appropriate experts. A financing plan built on an unrealistic filing date can exhaust cash before the next value inflection point.

Legal documents should make milestone definitions objective enough to determine whether later funding tranches are released.

Asset sale requires creditor-sensitive process. If the company sells its best patent or program while distressed, the board should consider whether the transaction is at fair value and whether it prejudices creditors. Independent valuation and a transparent sale process can reduce later challenge.

The company should also review consent rights, security interests and tax consequences before transferring core assets.

License-out can preserve upside with less capital. Instead of selling the whole asset, the company may license regional or therapeutic rights to a strategic partner for upfront and milestone payments. This can extend runway while retaining some future value.

The fund should compare licensing economics with outright sale and ensure the company owns the relevant rights and can grant exclusivity.

Management, employees and records in restructuring#

Management replacement may be part of restructuring. A financing failure can reflect strategy or execution rather than technology. A rescue investor may condition funding on a new CEO, CFO or development leader. Corporate approvals, employment arrangements and incentive plans should be addressed before the transition.

The fund should avoid changing management impulsively if the departing team holds essential regulatory or scientific knowledge.

Employee claims can affect cash and continuity. Distress can lead to delayed salary, bonus disputes or resignations. The company should remain current on mandatory employee obligations where possible and budget severance or retention carefully.

A rescue that ignores payroll risk may lose the very scientists needed to preserve enterprise value.

Data and records must survive a shutdown scenario. If operations cease, preserve laboratory records, regulatory submissions, source data, IP files, contracts and quality records. These records can be essential to sell or license the asset later.

The wind-down plan should assign custody and access rights rather than allowing systems to disappear when vendors stop service.

Strategic buyers, conflicts and exit decision#

Strategic buyers need a clean diligence package. The company should prepare a focused data room covering IP, regulatory status, clinical or technical data, key employees, contracts, liabilities and financing. A distressed sale moves quickly; missing documents can reduce price or cause the buyer to walk away.

The fund should not wait until cash is nearly exhausted to organize the company.

LP conflict procedures should be documented. If the manager operates another fund that could provide rescue capital or buy assets, conflict procedures are essential. The transaction may still be beneficial, but valuation, approval and allocation should be transparent.

The 2023 private-fund regulation emphasizes investor interests and conflict management, so managers should not treat affiliated rescue transactions informally.

Exit decision matrix. The fund should score each path—bridge financing, strategic sale, license-out, secondary transfer, restructuring and liquidation—against cash required, time, probability, creditor impact, governance complexity and expected recovery. A decision matrix prevents the loudest stakeholder from defining the outcome.

The recommended route should be updated monthly as cash and buyer interest change.

Distinguish fund extension from company rescue. The fund may need more time even if the portfolio company does not need more money. Extending the fund term and financing the company are separate decisions. An extension can allow orderly sale of an existing asset without committing additional capital; bridge financing increases exposure and should have its own approval and valuation analysis.

The manager should explain both decisions separately to LPs.

Watch for unequal treatment among co-investors. Different investors may hold different preference, information or consent rights. A rescue financing led by one investor can shift value if others cannot participate. The board and fund should examine pre-emption, anti-dilution and conflict rules before issuing new securities at a distressed valuation.

A transaction that saves the company can still create shareholder litigation if process is unfair.

Close the process with a documented choice. Whether the fund chooses sale, bridge financing or insolvency, the investment committee should record the assumptions, alternatives rejected and expected recovery. This is particularly important where the decision departs from the original IPO exit thesis.

A disciplined record helps demonstrate that the manager acted from current evidence rather than sunk-cost bias.

Downside governance and preservation of the decision record#

Final safeguard. Before committing more capital, the fund manager should be able to explain how the proposed rescue changes expected recovery compared with an immediate sale or insolvency path. If the answer depends only on management optimism, the fund has not completed its downside analysis. The decision should be supported by current cash flow, asset value, buyer interest, creditor position and a dated milestone plan.

Preserve the decision record. The investment committee should retain the cash model, valuation, buyer indications, legal analysis and minutes supporting its chosen route. Distressed decisions are often second-guessed after the outcome is known; a contemporaneous record shows why the manager considered the decision reasonable at the time.

Conclusion#

A distressed biotech investment requires the fund to think simultaneously as shareholder, potential lender and fiduciary manager. Contractual investor rights are only one part of the picture; cash runway, creditor priority, IP value and insolvency law determine the realistic options.

The central principle is: fund the rescue only if the rescue has a measurable path to value.

Legal and regulatory sources#

^[1] State Council Regulation on Supervision and Administration of Private Investment Funds, Decree No. 762, effective September 1, 2023: https://xzfg.moj.gov.cn/front/law/detail?LawID=1673

^[2] Company Law of the PRC (2023 Revision): https://www.npc.gov.cn/npc/c2/c30834/202312/t20231229_433999.html

^[3] Enterprise Bankruptcy Law of the PRC, official National People's Congress legal database: https://flk.npc.gov.cn/

^[4] Partnership Enterprise Law of the PRC, official NPC legal database: https://flk.npc.gov.cn/

General legal information only; not advice on a specific fund or portfolio company.